Article ID Journal Published Year Pages File Type
2123866 European Journal of Cancer 2010 9 Pages PDF
Abstract
Risk groups have been identified and validated that predict PSAD and OS in men with mCRPC and may facilitate evaluation of new systemic regimens warranting definitive testing in comparison with docetaxel and prednisone. Prospective validation of this classification system is needed.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Preview
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
Authors
, , , , , ,